MTM(SH:688029)2022-04-25 16:00Financial Performance - In 2021, the company achieved total operating revenue of CNY 1,946,723,952.08, representing a 46.77% increase compared to CNY 1,326,405,645.47 in 2020[23]. - Net profit attributable to shareholders was CNY 324,750,539.99 in 2021, up 24.54% from CNY 260,759,918.69 in 2020[23]. - The net profit after deducting non-recurring gains and losses was CNY 275,622,748.70, reflecting a 29.71% increase from CNY 212,491,554.10 in the previous year[23]. - The company's cash flow from operating activities was CNY 172,886,220.05, a decrease of 25.25% compared to CNY 231,272,060.53 in 2020[23]. - The company's total assets increased by 16.96% to CNY 3,631,746,826.61 at the end of 2021, compared to CNY 3,105,227,148.67 at the end of 2020[23]. - Basic earnings per share rose to CNY 2.4355 in 2021, a 24.54% increase from CNY 1.9556 in 2020[24]. - The company achieved a revenue of 1.947 billion RMB in 2021, making it the largest domestic manufacturer of endoscopic consumables[43]. - The company reported a significant increase in inventory levels due to extended transportation cycles caused by the pandemic[77]. Research and Development - The company invested 7.85% of its operating revenue in research and development in 2021, up from 7.51% in 2020[24]. - The company achieved a total R&D investment of ¥152,891,677.68 in 2021, representing a 53.40% increase from ¥99,668,625.72 in the previous year, with R&D expenses accounting for 7.85% of total revenue[53][54]. - The company has developed nearly 30 core technologies in endoscopic diagnosis and treatment, achieving multiple world-first and China-first innovations, including a new type of digestive tract stent and an endoscopic ultrasound minimally invasive treatment system[46]. - The company is enhancing R&D investment to accelerate new product development and upgrade existing products in the minimally invasive treatment device sector[46]. - The company has filed for 207 patents in total, with 73 new applications in the current year, including 6 new invention patents[52]. Product Development and Innovation - The company launched the "eyeMax Insight" biliary imaging system, marking a significant milestone in its development history[9]. - The company launched a disposable cholangioscopy system in November 2021, providing a new option for the diagnosis and treatment of biliary diseases[32]. - The company is focusing on the development of disposable endoscopes to reduce the risk of cross-infection and meet urgent clinical needs, with a trend towards miniaturization and complexity in design[45]. - The company is actively developing a series of hemostatic closure products, with the Lockado clip launched in the U.S. and plans for CE certification in 2022[55]. - The company has launched multiple new products in 2021, including the Single Use Coagulation Forceps and the Disposable Multistage Dilation Balloon Catheter, expanding its product portfolio significantly[93]. Market Expansion and Strategy - The company optimized its marketing structure in the U.S., Germany, and Asia-Pacific, and established subsidiaries in the UK and France while planning for a subsidiary in Japan[9]. - The company is committed to expanding its global footprint, with significant product introductions in Latin America and Southeast Asia[94]. - The company is strategically positioning itself to capture market share in the growing medical device industry through targeted product launches and regional expansions[96]. - The company is focused on expanding its presence in emerging markets, as evidenced by the launch of several products in Kenya and Sudan[101]. - The company aims to strengthen its global marketing strategy, particularly in the U.S. market, to enhance sales revenue and accumulate experience for other markets[115]. Corporate Governance and Management - The company held 4 shareholder meetings during the reporting period, ensuring equal treatment of all shareholders and facilitating participation through online voting[116]. - A total of 9 board meetings were convened, with directors diligently fulfilling their responsibilities and focusing on the company's operational status[116]. - The company has established a governance structure in compliance with relevant laws and regulations, continuously improving its governance level[116]. - The company has established a talent committee within the board to enhance governance and management capabilities[139]. - The company has a performance-based salary structure that includes basic salary, performance salary, and annual bonuses linked to company growth[154]. Financial Management and Investment - The company plans to distribute a cash dividend of CNY 7.50 per 10 shares, totaling CNY 100,310,415.00, which represents 30.89% of the net profit attributable to shareholders for 2021[158]. - The company confirmed a total share-based payment expense of CNY 77,052,516.97 during the reporting period[163]. - The company has engaged in litigation settlements and patent licensing agreements with Boston Scientific, reflecting ongoing strategic partnerships[139]. - The company has set a budget for 2021, with a focus on financial planning and resource allocation[138]. - The total external equity investment by the company in 2021 amounted to approximately RMB 179 million, an increase of about RMB 165.46 million compared to 2020[107]. Social Responsibility and Environmental Impact - The company has made donations to the Women and Children Foundation, reflecting its commitment to social responsibility[170]. - The company has established a comprehensive environmental management system and successfully passed the ISO14001 environmental management system audit without any non-conformities[178]. - The company has implemented measures to reduce carbon emissions, including VOCs management and resource conservation initiatives, contributing to sustainable development[179]. - The company achieved a greenhouse gas emission of approximately 3,800 tons during the reporting period, primarily from electricity consumption of 12.3 MWh and steam usage of 13,200 tons[174]. - The company has established a customer complaint handling process and a 400 sales consultation hotline to support customer service[187].